Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: Final results of Cancer Biotherapy Research Group 95-09

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 2, 2006, Pages 130-137

  Dillman, Robert O ^a   Wiemann, Michael C ^b   Tai, D Fritz ^c   Depriest, Carol B ^a   Soori, Gamini ^d   Stark, James J ^e   Mahdavi, Khosrow ^a   Church, Curtis K ^f  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b St Vincent Medical Center   (United States)

^c Bloomington Hospital   (United States)

^d Alegent Heallth Bergan Mercy Medical Center   (United States)

^e Maryview Medical Center   (United States)

^f MIDDLE TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Interferon ; Interleukin 2; Renal cell cancer

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOPHOSPHAMIDE; FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BOLUS INJECTION; BONE MARROW TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INFECTION; KIDNEY CARCINOMA; KIDNEY FAILURE; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RIGOR; SEIZURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 33744810634     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.130     Document Type: Article

References (26)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. Cancer J Clin 2005;55:10.
2. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261.
3. Flanigan RC, Salmon S, Blumenstein BA, et al. Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal cell cancer. N Engl J Med 2001;345:1655.
4. Mickisch GA, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal cell carcinoma: A randomised trial. Lancet 2001; 358:966.
5. Curti BD. Renal cell carcinoma. JAMA 2004;292:97.
6. Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal-cell carcinoma. Crit Rev Oncol Hematol. 2003;46(Suppl):S33.
7. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear-cell renal carcinoma. Clin Cancer Res 2004;10:5464.
8. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California-Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study. J Clin Oncol 2004;22:3316.
9. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: Development of an international kidney cancer working group. Clin Cancer Res 2004;10:6310S.
10. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530.
11. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 1995;22:42.
12. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alpha-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11:1368.
13. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410.
14. Dillman RO, Church C, Barth NM, et al. Long-term survival after continuous infusion interleukin-2. Cancer Biother Radiopharm 1997;12:243.
15. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;(Suppl 6):S55.
16. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopharm 1997;12:5.
17. Soori GS, Schulof RS, Stark JJ, et al. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: A National Biotherapy Study Group phase II study. Cancer Invest 1999;17:379.
18. Oldham RK, Blumenschein G, Schwartzberg L, et al. Combination biotherapy utilizing interleukin-2 and alpha interferon inpatients with advanced cancer: A National Biotherapy Study Group trial. Mol Biother 1992;4:4.
19. Dillman RO, Church C, Oldham RK, et al. Experience with high-dose continuous infusion interleukin-2 in the treatment of 788 cancer patients. Cancer 1993;71:2358.
20. Oldham RK, Dillman RO, Yannelli JR, et al. Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: A National Biotherapy Study Group. Mol Biother 1991;3:68.
21. Dillman RO, Schiltz PM, DePriest C, et al. Tumor-infiltrating lymphocytes and interleukin-2: Dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm 2004; 19:730.
22. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133.
23. Yang JC, Sherry RM, Steinberg SM, et al. J Clin Oncol 2003;21:3127.
24. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275.
25. Dillman RO. What to do with IL-2? Cancer Biother Radiopharm 1999;14:423.
26. Quan W, Jr, Ramirez M, Taylor C, et al. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm 2005;20:36.